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Abstract   
Astrocytes are the most abundant glial cell in the central nervous system and are involved in 
multiple processes including metabolic homeostasis, blood brain barrier regulation and neuronal 
crosstalk. Astrocytes are the main storage point of glycogen in the brain and it is well established 
that astrocyte uptake of glutamate and release of lactate prevents neuronal excitability and 
supports neuronal metabolic function. However, the role of lipid metabolism in astrocytes in 
relation to neuronal support has been until recently, unclear. Lipids play a fundamental role in 
astrocyte function, including energy generation, membrane fluidity and cell to cell signaling. There 
is now emerging evidence that astrocyte storage of lipids in droplets has a crucial physiological 
and protective role in the central nervous system. This pathway links β-oxidation in astrocytes to 
inflammation, signalling, oxidative stress and mitochondrial energy generation in neurons. 
Disruption in lipid metabolism, structure and signalling in astrocytes can lead to pathogenic 
mechanisms associated with a range of neurological disorders.  
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1. Introduction 
The brain is made up of a network of neurons, which are supported by various types of glial cells, 
with astrocytes being the most abundant [1, 2]. Astrocytes are involved in various crucial functions 
within the central nervous system (CNS), not least neuronal support. These roles are mostly 
beyond the scope of this review article but have been summarised extensively in recent articles 
[2-4]. An area of research that has emerged in recent years is the importance of lipid metabolism, 
storage and transport in both astrocytes and neurons [5]. Recent evidence suggests that 
disruption in neuron-astrocyte lipid crosstalk contributes to neurological disease pathology [6-8]. 
Therefore, the aim of this article is to discuss the role of lipids within astrocyte structure and 
function under physiological conditions, and how disruption to astrocyte lipid homeostasis can 
contribute to neurological disorders. To set the scene, this article will initially cover a brief 
introduction into astrocyte function in relation to metabolism, inflammation and neuronal support. 
Subsequently, astrocyte lipids will be introduced and discussed in the context of new insights into 
astrocyte membrane structure and membrane transport. Concomitantly, the role of astrocytic lipid 
mobilisation, will be discussed in the context of metabolic function, the emerging role of lipid 
droplet formation in astrocyte neuronal cross-talk and new insights into the role of lipids in CNS 
signalling pathways. Finally, the article will discuss the role of astrocyte lipids in relation to 
neurodegenerative diseases, highlighting potential therapeutic pathways and new avenues of 
research. 
1.1. Astrocyte support in the CNS 
Astrocytes are involved in numerous functions within the brain, including regulation of blood 
brain barrier (BBB) integrity, maintenance of extracellular ion and neurotransmitter homeostasis, 
and neuronal support [2-4]. Astrocytes support neurons in a multitude of ways, including 
neuronal growth and development during childhood [9] and neuronal maintenance throughout 
adulthood [10]. Communication between astrocytes and neurons is an important and tightly 
regulated process, thus making it essential for proper brain function [11]. Astrocyte membranes 
are enriched in glutamate transporters including glutamate transporter 1 (GLT1) and glutamate-
aspartate transporter (GLAST), which allow clearance of glutamate from the synapse of neurons 
after neurotransmission, preventing glutamate mediated excitotoxicity [12]. This communication 
is also crucial for maintenance of the health and normal function of the CNS, as well as 
providing both metabolic and trophic support [13]. 
 
1.2. Astrocyte metabolism 
Evidence suggests that neurotransmission uses the majority of energy in the brain [14] but 
neurons have very limited energy stores so they have to source their energy substrates such as 
glucose externally. However, there are tightly regulated mechanisms that ensure adequate 
delivery of the energy substrates in relation to the amount of neuronal activity occurring at any 
point [15]. Glucose is taken up by astrocyte projections through glucose transporter 1 (GLUT1) 
from peripheral blood circulation, concomitantly activating the glycolytic pathway [16]. For an 
excellent overview of glucose metabolism in the CNS see [17]. As astrocytes are predominantly 
glycolytic in nature [18, 19], glucose is oxidised to pyruvate and then dehydrogenated to lactate. 
If pyruvate is not dehydrogenated to lactate or taken up by the mitochondria and converted to 
acetyl-coA, gluconeogenesis can occur with excess carbon stored as glycogen for times of 
bioenergetic stress, however, this process is tightly regulated.  Using emerging fluorophore 
sensor technology, a recent study suggested that  mitochondria in cultured mouse astrocytes 
can maintain lower levels of pyruvate compared to the cytosol [20]. 
As pyruvate flux into the mitochondria is regulated by the mitochondrial pyruvate carrier (MPC), 
the authors suggest that this is an essential regulatory control point between basal respiration 
and gluconeogenesis in astrocytes. Therefore, this data suggests that modulation of pathways 
such as gluconeogenesis may have therapeutic potential in neurological diseases where there 
is a significant metabolic component such as Alzheimer's disease (AD, see Zulfiqar et al for a 
recent review see [21]). For example, astrocytes expressing the E4 allele of Apo-lipoprotein E 
(APOE), a genetic risk factor for AD, were shown to have increased glucose flux via the pentose 
phosphate pathway (PPP). This led to a concomitant increase in gluconeogenesis as well as 
phospholipid and nucleotide biosynthesis compared to E3 astrocytes [22]. Moreover, an 
increase in gluconeogenesis was observed when the neurosteroid tibolone was used to reduce 
L-glutamate-mediated neurotoxicity in astrocytes [23]. Tibolone has previously been used to 
reduce inflammation in neurons, however emerging mechanistic analysis in murine cortical 
astrocytes subject to brain injury has shown that the drug also reduces reactive astrocyte levels, 
indicating an anti-inflammatory role in glia [24]. 
 
1.3 Inflammation 
Astrocytes play an important role in CNS inflammation and undergo a range of functional and 
structural adaptations termed astrogliosis in response to inflammatory conditions induced by 
metabolic stress, infection or injury for an in depth review see [25].   
Astrogliosis can exert either protective or harmful effects depending on the extent of gliosis and 
the specific signalling pathways activated, with evidence suggesting both inflammatory and anti-
inflammatory pathways can be activated. Astrocytes have been shown to stimulate the release 
of, for example, the anti-inflammatory cytokine TGF-β, in response to IL-10, which attenuates 
inflammation in microglia [26]. Conversely astrocytes have been shown to release the pro-
inflammatory cytokines Tumour Necrosis Factor-α (TNF-α) and Interleukin-1β (IL-1-β), as well 
as releasing CC-chemokine ligands (CCCL) and CXC-chemokine Ligands (CXCL). Certain 
CCCLs and CXCLs, along with TNF-α, are responsible for recruiting a diverse range of 
leukocytes by inducing and activating their adhesion molecules [27]. IL-1-β stimulates 
astrocytes to release vascular endothelial growth factor, which increases the ability for 
leukocytes to cross the BBB and enter the CNS parenchyma [28]. 
There is a bi-directional relationship between inflammation and metabolic status not only in 
astrocytes but in the CNS as a whole, which is an emerging area of therapeutic research in 
neurological diseases [29-31]. Preventing astrocyte inflammation through nuclear factor-kappa 
B (NF-κB) inhibition in mice astrocytes for example, has been shown to be beneficial by; 
reducing glial scarring in spinal cord injury; increasing glucose tolerance and promoting energy 
expenditure; and increasing glucose uptake and glycolytic capacity. Moreover astrocytic 
glycolytic inhibition by 2-deoxyglucose has recently been shown to significantly reduce LPS-
induced cytokine release and NF-κB phosphorylation [32-34]. There is also emerging evidence 
of a link between astrocyte lipid signalling and the metabolic inflammatory response which will 
be discussed in section 2. 
 
1.4 Astrocyte metabolic support of neurons 
Astrocytes have been proposed to support neurons metabolically via the release of lactate [35], 
however this is still a controversial area. In order for this theory to remain true, it was proposed 
that neuronal glucose metabolism does not occur in an activity dependent manner, and that 
lactate is the preferred neuronal substrate. Contrary to this however, it is now well established 
that glucose transporters are present in neuronal membranes, indicating that they have the 
potential to transport and metabolise glucose [36, 37]. Moreover, studies have shown that whilst 
there is significant intracellular production of lactate in the brain, lactate uptake remains 
relatively slow. This is in opposition with the theory of lactate being used as a major neuronal 
fuel source [38]. The astrocyte-neuron lactate shuttle hypothesis, originally hypothesised by 
Pellerin and Magistretti, [39], states that neurons stimulate glycolysis in astrocytes through 
glutamate release. Uptake of synaptic glutamate from the neuronal synapse by astrocytes 
activates Na+/K+ ATPase’s due to the increased cellular uptake of Na+ which is co-transported 
with glutamate and consumes the ATP produced by phosphoglycerate kinase [39]. This triggers 
astrocyte glucose uptake via GLUT1, and concomitantly glycolysis which produces pyruvate 
that is converted to lactate via lactate dehydrogenase (LDH). Lactate is transported out of cell 
via monocarboxylate transporter 1 (MCT1) and taken up by neurons via MCT2. LDH converts 
this back to pyruvate for re-entry into the TCA cycle via acetyl CoA [40] (Fig 1). In this way 
lactate can contribute to the activity-dependent energy demands associated with neuronal 
synaptic transmission [41]. Glutamatergic stimulation of astrocytic lactate production has been 
recently challenged due to the fact that; significant lactate oxidation has not been shown during 
brain activation, glial glutamate transporter GLAST forms a macromolecular complex linking 
glutamate uptake with its oxidation and as previously mentioned, neurons express glucose 
transporters and both take up and metabolise glucose [36, 42-44].  
 
1.5 Astrocyte metabolic fuel storage 
Glycogen is one of the major fuel sources for both astrocytes and neurons in the human CNS 
and is stored when glucose is in excess. Interesting recent findings have shown that high 
glucose exposure in astrocytes can lead to increased glycogen storage but at the expense of 
decreased mitochondrial and glycolytic capacity when subsequently metabolically stressed [16]. 
This has implications for neurodegenerative disorders with a significant astrocyte metabolic 
phenotype including amyotrophic lateral sclerosis (ALS). The data suggest astrocytes under 
metabolic stress have less capacity to sustain energetic cellular requirements, which would 
impact the ability of astrocytes to metabolically support neurons for example and is aligned with 
data produced from our laboratory [19]. 
Astrocytic glycogen that is concomitantly utilised by neurons, has been proposed to be a store 
for lactate, rather than glucose, which (as described above) could potentially supply the needs 
of nearby CNS cell populations [37, 45, 46]. As well as glycogen, astrocytes synthesise and 
release various lipid moieties including sterols, fatty acids and triglycerides as well as storing 
phospholipids and sphingolipids in the plasma membrane [47-51]. Neurons do not store 
glycogen and synthesise lipids less efficiently than astrocytes [52]. Therefore, neurons take up 
astrocyte-derived lipids in order to support the formation and function of the synapses [53]. 
There are a variety of lipid classes in astrocytes that play multiple roles in astrocyte function, the 
intracellular localisation of these lipid classes are highlighted in Figure 1 with new insights 
discussed in the following section.  
 
2. Lipids in Astrocytes  
 
2.1. Cholesterol  
Cholesterols are the major form of sterol lipid in the brain. Whilst the majority of sterol synthesis 
occurs in oligodendrocytes in the developing brain and is associated with myelin production 
[54], astrocytes are considered to be the main net producer of cholesterol in the CNS. 
Conversely, neurons are considered to be the net consumer [52]. Astrocyte cholesterol 
metabolism is independent of the rest of the cholesterol metabolism in the body, due to the 
presence of the BBB [55]. Cholesterol is one of the most important molecules of the synaptic 
membrane, in which it regulates a multitude of biochemical processes including membrane 
fluidity and ion channel function [53]. Of all the lipids present in astrocytes, cholesterol may have 
the most important role in astrocyte structure. Cholesterol helps regulate cell membrane 
flexibility, through interactions with nearby phospholipids [56]. Other important roles for 
cholesterol have also been identified, including lipid raft formation, glucose transport and 
inflammatory signalling [57-59]. Up to 70% of cholesterol is synthesised de novo in hepatic cells 
in the liver, with the remaining being derived in the intestines from dietary intake. This 
cholesterol is then circulated to all areas of the body via lipoprotein lipid-transfer.  
The BBB, however, allows only High Density Lipoproteins (HDL’s) to enter the brain: as a result, 
lipoproteins found in the brain must have been produced in the CNS. Brain cholesterol is 
therefore believed to be synthesised de novo [60] and is considered the most cholesterol rich 
organ, accounting for around 25% of the total cholesterol content in the body. Estimates based 
on mouse models of the CNS suggest 80% of cholesterol is contained in myelin sheaths [54]. 
Nieweg et. al. [52] demonstrated that astrocytes primarily synthesise cholesterol via the Block 
pathway, and neurons via the Kandutsch-Russell pathway. In addition, cholesterol levels are 
higher in astrocytes with lower expression of cholesterol synthesising enzymes in neurons, 
suggesting neurons derive cholesterol externally [52]. Astrocytes are therefore believed to be 
the main site of cholesterol synthesis, which is an ATP-dependent process that occurs in the 
endoplasmic reticulum (ER) [61]. Cholesterol is then rapidly shuttled to the plasma membrane in 
vesicular and protein-mediated transport systems. Astrocytes also synthesise lipoproteins and 
Apo-lipoproteins for cholesterol transport [62]. Cholesterol-carrying lipoproteins cannot cross the 
BBB to enter the brain readily [63], highlighting the importance of astrocyte-derived cholesterol 
synthesis for glia and neurons. The significance of cholesterol synthesis in astrocytes has been 
demonstrated in studies investigating sterol regulatory element binding protein 2 (SREBP2), a 
transcription factor for several genes involved in sterol synthesis [48, 53, 64]. Astrocyte-specific 
depletion of SREBP2 produced profound effects in mice brains, such as reductions in neurite 
outgrowth, brain size and brain mass. Additionally, changes in liver mass, physical activity, 
motor coordination, memory and a shift towards carbohydrate metabolism were also observed. 
Reductions in brain cholesterol synthesis have been demonstrated in insulin-deficient mice [64]. 
These changes suggest astrocyte cholesterol synthesis may have an important role in metabolic 
disorders.   
In addition to its role in membrane structure, cholesterol has also been shown as an important 
regulator of the activity and localisation of a range of membrane proteins [59, 65]. Membrane 
regions enriched with cholesterol and sphingolipids form lipid rafts and are understood to be a 
key regulator of activity of several membrane proteins [57]. An example of this is Toll Like 
Receptor 4 (TLR4), a receptor that promotes inflammation. Dimerisation of TLR4 is essential for 
its activation and occurs largely in cholesterol-rich membrane regions [66, 67]. In addition to 
receptors, membrane transporter protein levels can also be influenced by the cholesterol content 
of membranes. Depletion of membrane cholesterol leads to increases in GLUT1 trafficking to the 
membrane, which is accompanied by an increase in glucose transport [58]. In our laboratory we 
coined the phrase metabolic flexibility, in relation to the ability of astrocytes to mobilize and 
catabolise alternative energy substrates to meet bioenergetic demand [18]. We proposed that a 
contributing mechanism to reduced metabolic flexibility observed in astrocytes derived from ALS 
patients was impairment of the transport of metabolic substrates across membranes. We 
surmised this was linked to alterations in cholesterol levels as energy production in the presence 
of mitochondrial specific substrates was reduced in ALS astrocytes compared to controls. 
However, treatment of astrocytes with saponin which binds to cholesterol to permeabilize 
membranes, restored mitochondrial substrate energy production in ALS astrocytes to levels 
comparable with control astrocytes. Cholesterol levels have previously been implicated  in ALS, 
with  increasing evidence emerging that cholesterol levels are lower in ALS patients [68, 69] and 
that higher serum cholesterol may prolong survival in patients [70].  
This emerging area of study requires more mechanistic research into the role of membrane 
cholesterol and of metabolic substrate transport. However, therapeutic targeting of this pathway 
could enhance astrocyte metabolic flexibility and increase metabolic support to neurons which 
has the potential to modify disease progression in many neurodegenerative disorders.  
 
2.2. Sphingolipids 
Sphingolipids are a class of lipids characterised by the presence of a sphingosine backbone. This 
includes a range of lipids including ceramide, sphingosine and sphingomyelin. A range of different 
cellular functions for sphingolipids have been described. Sphingolipids are a key structural 
component for membranes, including lipid rafts [57]. Metabolites of sphingolipids have recently 
been identified as important regulators of inflammation, autophagy, cell growth and survival [71-
73]. For an extensive recent review of sphingolipids, see Hannun and Obeid [74] and for a review 
of sphingolipids in the nervous system, see Schnaar et al  [75].  Several roles of sphingolipids in 
astrocyte function have also been described, including inflammatory regulation [76]. Numerous 
changes to sphingolipid structure and metabolism have been described in astrocytes from 
patients with various neurodegenerative diseases [48, 77-79] and will be discussed later in the 
article. Modifications to ceramide sphingolipids such as glycosylation to produce gangliosides, 
have already been associated with neurodegeneration [80-83]. Membrane ganglioside 
interactions with amyloid beta accelerate plaque formation in AD [84, 85] and inhibits alpha-
synuclein fibrillation [86, 87]. Antibody-mediated ganglioside clustering can activate signalling 
pathways that inhibit neurite outgrowth [88, 89]. Sphingolipids are heavily enriched at synapses, 
and production is required for regulation of synapse structure and output [90]. It is currently 
hypothesised that normal production of gangliosides by astrocytes also enhances neurite 
outgrowth, regulates neuronal inflammation and stabilises neuron-glia interactions [83]. These 
findings highlight the importance of sphingolipids in the functioning nervous system, and 




Phospholipids are a vital component of cell membranes, making up the majority of the 
“phospholipid bilayer”. As with other lipids mentioned, phospholipids are also synthesised heavily 
in the brain [91]. There are several classes of phospholipids, including phosphatidylcholine, 
phosphatidylserine, phosphatidylethanolamine and phosphatidylinositol. For a recent review of 
these lipids in the brain, see Tracey et al, [5]. In addition to their importance in cellular structure, 
exposure of neural cells to different phospholipids influences cell fate. Acting through the 
MAPK/ERK pathway, treatment of neural cells (including post-mitotic cells) with 
phosphatidylethanolamine, increased differentiation of cells into astrocytes [92]. In contrast, 
phosphatidylcholine treatment reduced astrocyte differentiation. Phosphatidylethanolamine can 
bind to phosphatidylethanolamine binding protein (PEBP1) which can inhibit the MAPK/ERK 
pathway [93], suggesting the lipid may act by binding to PEBP1 and preventing it from inhibiting 
the MAPK/ERK pathway (Fig 2). 
 
2.4. Free fatty acids  
Free fatty acids, also known as Non-Esterified Fatty Acids are fatty acid molecules that are not 
bound to glycerol. Effects of exposure of astrocytes to free fatty acids are beginning to be 
characterised, with current evidence showing their ability to modulate inflammation. When treated 
with saturated fatty acids such as palmitic acid, an increase in pro-inflammatory cytokine 
production by astrocytes has been observed [94]. Several mechanisms have been proposed for 
this in astrocytes including increased ceramide production and activation of p38 or p42/44 MAPK 
pathways [94, 95]. In cells such as macrophages, palmitic acid has been identified as a TLR 
agonist, and can increase ROS production through mitochondrial complex I/III inhibition [96-98].  
Conversely, polyunsaturated fatty acids (PUFA’s), such as the omega-3 fatty acid 
docosahexaenoic acid (DHA), are increased in astrocytes during inflammation including 
palmitate-induced inflammation, suggesting that DHA may have anti-inflammatory properties [94, 
99, 100]. Moreover, in microglia, DHA treatment inhibits NF-kB signalling, concomitantly 
increasing ROS production, leading to raised expression of HO1 via Nrf2 activation [100, 101]. In 
vivo models and human plasma analysis in ALS patients suggests gender-specific effects of DHA 
exists: DHA levels are raised significantly in men but not women, and DHA supplementation 
increased survival in male SOD1-ALS mice, but not females [102, 103]. Further characterisation 
of gender-specific differences in responses to DHA could help identify its effectiveness as a 
potential treatment for diseases such as ALS or AD, both of which feature inflammation as a 
pathogenic mechanism.  
In addition to in vitro studies, astrogliosis has been documented extensively in rodent models in 
response to a high fat diet (HFD) in a range of brain structures, including the nucleus of the solitary 
tract, hypothalamus and substantia nigra [104-108]. Studies have documented the appearance 
of astrogliosis over a range of time periods: from acute 12hr responses [109] to 5 months after 
initiation (chronic) [108], although astrogliosis is usually more subdued after chronic HFD 
exposure. The significance of this astrogliosis response to a HFD has been investigated in 
connection to feeding behaviour of mice. Astrocyte-specific inhibition of NF-kB signalling to 
prevent astrogliosis, produced a 15% higher caloric intake in mice after acute HFD feeding [106]. 
Chronic HFD feeding caused glial ensheathment of pro-opiomelanocortin (POMC) synapses, 
potentially reducing inhibitory appetite signalling [104]. Taken together, these findings suggest 
exposure to elevated fatty acid levels after a HFD can induce astrogliosis, which has a role in 
maintaining energy homeostasis and may become dysregulated during chronic HFD exposure 
(Fig. 3). Targeting hypothalamic astrogliosis during obesity may restore appetite signalling and 
normal energy homeostasis. 
 
In addition to membrane structure, inflammatory regulation and regulation of cell fate, astrocyte 
transport of lipids to neurons for use in metabolism is a crucial part of the astrocytic-neuronal 
communication axis. As astrocytes allow neurons to access their cellular resources, this enables 
metabolism to be maintained throughout higher levels of neuronal activity [8]  which is crucial in 
both physiological and pathological conditions.  
 
3. Lipid metabolism and storage in astrocytes and its role in neuron-astrocyte crosstalk 
Current findings continue to highlight the importance of astrocytes in the maintenance of brain 
homeostasis, with an increasing focus on the ability of these cells to influence neuronal function. 
Lipid metabolism is crucial to normal astrocytic function and therefore a key intermediate in 
neuron-astrocyte crosstalk. The following section highlights recent findings regarding the role of 
lipid metabolism in astrocyte metabolic support of neurons, and the role of astrocyte lipid 
signalling in neuronal morphology and synaptic transmission 
3.1. Fatty acid oxidation and Lipid Droplets 
Lipid droplets (LDs) are a fundamental component of lipid metabolism in astrocytes. LDs are 
ubiquitous cellular organelles that regulate the storage and hydrolysis of fatty acids in 
eukaryotes, forming rapidly in response to increased fatty acid levels and vice versa when fatty 
acids are depleted [110]. LDs consist of a core of neutral lipids made up of mostly cholesteryl 
esters, triacylglycerol and ether lipid monoalk(en)yl diacylglycerol, surrounded by a monolayer 
of phospholipids and proteins [111-113]. Though the process isn’t fully elucidated it is thought 
LDs form in a triphasic process in the ER (Fig.4). Initially, fatty acids are nucleated, then 
undergo a growth phase after which they bud off and enter the cytosol. This theory has been 
supported by cryoelectron microscopy and immunocytochemical analysis [113, 114]. The 
droplets are then broken down by lipases via lipolysis, the rate limiting step of which is carried 
out by adipose triglyceride lipase [115]. The neutral lipids used in this process are derived from 
de novo synthesis from other fatty acids in the ER [116, 117]. In astrocytes, this may include 
excess fatty acids from neurons [8] and dietary fatty acids that cross both the BBB and 
astrocyte/neuron membranes via fatty acid binding proteins (FABPs) [118-120] (Fig. 4). FABPs 
are lipid chaperones in cells that regulate the response of lipids to stimuli. FABP7 is the major 
isoform in the brain, however, FABP3 and FABP5 are also expressed [121]. Astrocytic-FABP7 
plays a role in dendritic morphology and synaptic transmission [122], sleep [123] schizophrenia 
[124] and Down syndrome [125].  
The main purpose of LD generation is to provide fuel for β-oxidation. β-oxidation of LDs in the 
mitochondria provides an alternative energy generation pathway in times of starvation in several 
tissues, including astrocytes. Nutrient deprivation in rat primary astrocytes demonstrated β-
oxidation of LDs was crucial to the maintenance of cell viability during stress [126]. Moreover, 
inducing recurrent low glucose in human primary astrocytes led to a switch to fatty acid 
metabolism for energy production [127]. Evidence also suggest energy derived from β-oxidation 
in astrocytes metabolically supports neurons [8]. Furthermore, some argue that fatty acid 
oxidation (FAO) plays a more prominent role than that of a backup to glucose metabolism. Most 
reports consider glucose metabolism as the main or only method for metabolism in the brain 
[128]. However, it has been estimated upwards of 20% of energy generation in the brain is 
generated via FAO [129, 130].  Panov et. al. [128] argue FAO occurs concomitant with glucose 
metabolism based on the evidence that in vitro, astrocytes metabolise fatty acids alongside 
other metabolites. Eraso-Pichot et. al. [131] utilising bioinformatic analysis, showed an 
upregulation in FAO genes in human primary astrocytes. They also demonstrated FAO 
occurring in tandem with glycolysis in vitro, suggesting a precedent for FAO in the brain. FAO of 
LDs plays an undeniably important role in maintaining astrocyte-neuron homeostasis and further 
research stands to only emphasise this. 
 
3.2. Astrocyte Lipid Signalling 
3.2.1 Neuronal Morphology 
Studies suggest that astrocyte-neuron crosstalk goes beyond providing metabolic support. 
Emerging evidence demonstrates astrocyte signalling and lipid metabolism mediates neural 
circuit function and formation. One example of this is in neural circuit outgrowth, a process 
which is known to be influenced by astrocytes [132]. Recent evidence suggests this process is 
carried out via the action of phosphatidic acid (PA) [133]. PAs are phospholipids important for 
signalling and activation of lipid-gated ion channels [134] and have long been linked to neurite 
outgrowth [135, 136]. PAs are synthesised by phospholipase D1 (PLD1) and 2 (PLD2) which 
hydrolyse phosphatidylcholine to form PA and choline [137] and diacylglycerol kinase (DGK) 
[138] which phosphorylates diacylglycerol (DAG) to produce PA. This process is important for 
both astrocytes and neurons; in neurons DGK knockout attenuates synaptic vesicle recovery at 
the presynaptic terminal [139], PLD1 dysfunction is linked to impaired neurite outgrowth in 
Alzheimer’s [140] and PLD2 ablation rescues synaptic function [141]; and in astrocytes, 
knockout of PLD1 and 2 reduces astrocyte proliferation in culture [142]. Zhu et. al. [133], 
demonstrated that when PLD1 was knocked down or inhibited in rat hippocampal astrocytes in 
co-culture with neurons, neuronal dendritic branching reduced significantly. PA addition restored 
dendritic branching and increased dendritic outgrowth. Furthermore, astrocyte conditioned 
media recapitulated these effects, demonstrating that PLD1 dendrite outgrowth was mediated 
by PA generation and release from astrocytes. It is possible the process may regulate secretion 
of extracellular vesicles as these processes are known to affect morphology of neurons 
amongst other roles [143]. Inhibition of protein kinase A (PKA) reduced PA-stimulated dendritic 
outgrowth, but not fully, suggesting PKA signalling, which has been shown previously to 
influence dendrite outgrowth [144] was not the sole mechanism by which PA influences neurite 
outgrowth. PLD1 has also recently been shown to affect protein kinase-D1 which affects 
dendritic spine morphogenesis; thus this could be another area of influence for astrocytic PA 
[145]. ]. Therefore, astrocyte PA clearly has an important role in shaping neuronal morphology. 
 
3.2.2. The endocannabinoid system and the neuronal synapse 
The endocannabinoid (ECB) system is made up of G-protein-coupled cannabinoid receptors 
(CBRs) that are activated by ECBs, lipid-based eicosanoid neurotransmitters such as 
anandamide and 2-arachidonoylglycerol (2-AG) [146, 147] . The system has regulatory roles in 
heart, liver and brain function and has been widely studied for its potential role in astrocyte-
neuron communication [148, 149]. ECBs are synthesised generally in response to G-protein 
coupled receptor activation or depolarization, with 2-AG being synthesised from diacylglycerols 
(DAGs) by DAG lipases and phospholipase C [150, 151] whilst anandamide is synthesised from 
N-acyl-phosphatidylethanolamine by PLD [152]. Two CBRs have been characterised in the 
human body, CBR1 [153] and CBR2 [154]. CBR1 is highly expressed in the brain where it 
mediates most notably mood, cognitive ability, appetite and the pharmacological effects of 
cannabis, and is highly important for the control of synaptic transmission. Navarette and Araque 
[148], showed depolarization in pyramidal neurons of the rodent brain leads to ECB release, 
activating astrocyte CBR1 receptors triggering phospholipase-C dependent Ca2+ release from 
astrocytes. This stimulated glutamate release, activating N-methyl-D-aspartate (NMDA) 
receptors in the pyramidal neurons. The same phenomenon has also been reported in the 
human brain [155]. 
Astrocytes also influence long-term changes in synaptic transmission. Spike-timing dependent 
plasticity is a process in which neurons adjust the strength of their signals dependent on the 
timing of input and output action potentials [156], which influences neuronal circuit development 
[157]. Min and Nevian [158], demonstrated that activation of astrocytic CBR1 receptors leads to 
a transient increase in Ca2+ levels and Ca2+ signalling. Subsequent astrocyte glutamate release 
then activates NMDA receptors which triggers ECB mediated spike timing-dependent long term 
depression (t-LTD), showing the vital role astrocyte-ECB interaction plays in t-LTD and thus 
neuronal development. More recent studies have also shown a contrary role for CBR1 in long-
term potentiation (LTP). Mice with a CBR1 knockout demonstrate reduction in LTP at 
hippocampal synapses, whereas CBR1 receptor activation increased exogenous D-serine 
levels (which is needed for LTP [159]), thus CBR1 controls synaptic D-serine and therefore LTP 
[160].  
The endocannabinoid system has also garnered recent attention because of its potential health 
benefits, with the UK government recently shifting cannabis-based products from schedule 1 to 
schedule 2 in the Misuse of Drugs Regulations 2018. The most widely studied cannabinoids are 
tetrahydrocannabinol (THC) and cannabidiol (CBD). THC works purportedly via activation of 
CBR1 [161, 162] whilst CBD has low affinity for CBRs, instead acting as an antagonist of CBR 
agonists [163]. Nabiximols (a.k.a. Sativex), a CBD/THC mix, purified from Cannabis sativa L. is 
prescribed as an analgesic [162, 164, 165], and alleviates the negative effects of cannabis 
withdrawal [166]; whilst Nabilone (a.k.a. Cesamet) and Dronabinol (a.k.a. Marinol®/Syndros) 
are synthetic cannabinoids that mimic THC and may be effective as antiemetic’s [167, 168] and 
analgesics for diseases such as multiple sclerosis and fibromyalgia [169-171]. A recent meta-
analysis of cannabinoids as therapeutics showed moderate support for the alleviation of chronic 
pain and spasticity, low support for cannabinoids as analgesics, and an increased risk of 
adverse events [172]. The suggestion that cannabinoids can treat mental disorders like anxiety 
and depression may also be misplaced as a recent review analysing the available literature on 
THC used therapeutically (with or without CBD) to treat mental disorders highlights [173]. 
Black et al. (2019) show only a few investigations report an improvement in anxiety in treated 
patients (but only in individuals with a pre-existing condition). No improvement was reported in 
other conditions (such as depression) though multiple studies highlight the increased risk of 
adverse events and adverse events due to withdrawal. Cannabinoids therefore have therapeutic 
potential, but further research, particularly concerning true efficacy and long-term effects are 
required and wide-spread use of cannabinoid-based therapies in the near future seems unlikely. 
 
4. How defective lipid metabolism in astrocytes contributes to CNS disorders 
In the previous sections we discussed for the most part the role of lipid metabolism in the 
physiological context. For the remainder of the review, we will discuss the new insights that 
have recently emerged linking disruption with astrocytic lipid metabolism and neurological 
disorders. 
It is well established that metabolic dysfunction influences pathogenesis of a number of 
neurodegenerative disorders including ALS, PD and AD, for in depth reviews see [174-176]. 
The role of astrocytes in disease pathogenesis in ALS for example is well established with new 
astrocyte associated disease relevant pathways being recently identified using human models 
of disease combined with novel approaches such as phenotypic metabolic profiling [10, 18, 19]. 
The role of astrocytes in PD and AD is less well established but studies are emerging linking 
astrocyte metabolic defects with inflammation, BBB disruption and neuronal loss [177-181]. The 
role of lipid metabolism dysfunction as a whole in the CNS is outside the remit of this review 
article and has been covered by other authors in recent review articles [5, 182]. However, in this 
final section we will focus on the role of astrocytic lipid metabolism, signalling and inflammation 
in the context of CNS disorders and we will discuss the emerging role of manipulating astrocyte 
lipid metabolism as a therapeutic approach. 
4.1. Astrocyte LDs in disease. 
As previously mentioned, effective neuronal function is intrinsically linked to astrocyte 
metabolism and cross talk exists where oxidative stress in neurons triggers LD formation in 
nearby astrocytes which can lead to neurodegeneration via lipid peroxidation [6, 7]. This 
formation is dependent on Apo lipoproteins and the neuron-glial lactate shuttle [183]. Inhibition 
or deletion of glial and neuronal MCTs reduced LD accumulation in mouse glial-neuronal co-
cultures and Drosophila respectively. Whilst inhibition of neuronal lactate production and fatty 
acid transport proteins had similar effects in flies. Recent work by Ioannou et. al. [8, 184] 
demonstrated that hyperactive neurons accumulate peroxidated lipids and expel them in 
association with APOE-positive lipid particles. These particles are then concomitantly 
endocytosed by neighboring astrocytes, which incorporate the lipids as droplets. Moreover 
during increased neuronal activity, astrocytes upregulate antioxidant genes and breakdown LDs 
to fuel oxidative phosphorylation. However, the precise role of astrocyte LDs is still unclear as 
are the role of astrocyte LDs in neuroprotection or as a driver of neurodegenerative disorders [6, 
185].  This is an avenue of research which is likely to attract a great deal of attention over the 
next few years due to the potential therapeutic benefits to multiple CNS disorders of 
understanding the associated mechanisms. For example, accumulation of LDs in astrocytes has 
recently been observed in murine  models of ALS, and the role of LDs in motor neuron diseases 
has been recently reviewed [186]. Moreover, in AD it was found that astrocytes expressing the 
E4 APOE allele accumulated higher amounts of LD, and had both decreased fatty acid uptake 
and decreased fatty acid oxidation compared to E3 astrocytes. Furthermore, E4 astrocytes were 
more sensitive to carnitine palmitoyltransferase-1 inhibition than E3 astrocytes indicating a 
preference for mitochondrial fatty oxidation [187]. In a mouse model of Leigh Syndrome where 
the mitochondrial complex I component Ndufs4 was knocked out, neuronal mitochondrial 
abnormalities led to pre-symptomatic glial LD accumulation [6]. This highly significant study 
suggested that LD accumulation may represent an early indicator and/or promoter of 
neurodegeneration. Furthermore, targeted lipase overexpression or lowering ROS levels in 
Drosophila, reduced LD accumulation in glia, potentially delaying the onset of 
neurodegeneration [6]. FABPs are important for LD synthesis in response to reactive oxygen 
species. Knockout of FABP7 in primary mouse astrocytes caused reduced LD formation, 
increased ROS toxicity and impaired thioredoxin signalling in response to ROS induced stress, 
activating apoptosis signalling pathways. Conversely, overexpression of FABP7 in a human-
glioma line increased LD accumulation and expression of antioxidant defence pathways [188], 
suggesting FABP7 protects astrocytes from oxidative stress via generation of LDs, which has 
implications for multiple neurological diseases with oxidative stress as a pathological 
mechanism.  
4.2. Astrocyte lipid signalling and inflammation in disease  
A mechanism of dysfunction exists between LDs and lipid signalling in the CNS.  Lipoprotein 
lipase (LPL) is a serine hydrolase that releases free fatty acids from circulating triglyceride-rich 
lipoproteins and has previously been implicated in CNS metabolic regulation [189]. A recent 
study showed that LPL loss in mice hypothalamic astrocytes led to decreased LD content [47]. It 
was suggested that LPL mediates lipid partitioning and is needed for nutrient sensing and 
energy homeostasis regulation in the CNS. LPL deficient mice suffered glucose intolerance and 
weight gain when fed a HFD, as well as a compensatory upregulation of lipogenesis-related 
genes, glycolytic flux and ceramide. 
Ceramide is an important multifunctional intracellular signaling molecule where alterations in 
levels have been linked to neurological diseases. Recently, a connection was suggested 
between ceramide levels and inflammation in frontotemporal lobar dementia (FTLD) patient 
astrocytes [79]. Moreover, in patients with Pick’s disease, (a form of frontotemporal dementia), 
ceramide 16:0 levels were shown to be raised in astrocytes but not in other forms of glia, such 
as microglia. Although these lipids compose a small fraction of total ceramide from the 
membrane, increases in astrocyte ceramide 16:0 have previously been observed in active 
multiple sclerosis lesions (with increased acid sphingomyelinase expression), have been 
observed in AD patients and have been linked to increased apoptosis in cells  [77, 78, 190]. 
These data in combination with the increase in ceramide and sphingosine-1-phosphate receptor 
3 levels observed in astrocytes from patients with capillary cerebral amyloid angiopathy [191], 
potentially indicate a common pathogenic mechanism between neurological diseases.  
As previously mentioned, dietary fatty acids have also been shown to modulate inflammation. 
Conjugated linoleic acid has been shown to alter the levels of TNF-α, IL-1β, and RANTES in 
cultured human astrocytes [192]. Within the context of ischemia, intravenous injection of α-lipoic 
acid reduced neuronal damage in a rat model of ischemia but did not reduce astrogliosis [193]. 
Whilst inhibition/deletion in mice of (seladin-1)3β-Hydroxysteroid-Δ24 reductase (DHCR24), (a 
cholesterol biosynthetic pathway enzyme), led to increased ischemic lesion and inflammation 
after middle cerebral artery occlusion [194]. Loss of seladin-1/DHCR24 as observed in AD 
brains, decreased plasma membrane cholesterol levels and concomitantly the formation and 
stability of lipid rafts. In mice, loss of seladin-1/DHCR24 led to a decreased association of the 
glutamate transporter EAAT2 with lipid rafts and decreased glutamate uptake in astrocytes. 
These data indicate that DHCR24 mediated lipid raft integrity plays a crucial protective role in 
the ischemic brain by guaranteeing EAAT2-mediated uptake of glutamate excess. These highly 
significant results link cholesterol, inflammation and lipid raft integrity to EAAT2-mediated 
uptake of glutamate excess via seladin-1/DHCR24.  This has implications for a variety of 
neurological disorders including ischemia, AD and ALS with similar pathways observed in 
psychiatric disorders.  
4.3. Is astrocyte lipid pathway manipulation beneficial in neurological disorders? 
The synaptic phospholipid, lysophosphatidic acid (LPA), has been shown to regulate cortical 
excitation/inhibition balance and sensory information processing [195-197]. In a recent study, 
the LPA-synthesizing enzyme autotaxin (ATX) which is expressed in the astrocytic compartment 
of excitatory synapses modulating glutamatergic transmission was found to be sorted to 
excitatory not inhibitory synapses [198]. This sorting was regulated by neuronal activity via 
astrocytic glutamate receptors. Therefore, pharmacological ATX inhibition has been proposed 
as a method to reverse cortical hyperexcitability in schizophrenia, suggesting that manipulating 
astrocytic lipid function may be a viable therapeutic approach in neurological disorders. But is 
that the case? 
The ability to manipulate catabolic pathways to increase carbon flow through those pathways or 
to  mobilise internal energy stores such as fatty acids in times of bioenergetic need may be a 
viable metabolic based therapeutic approach. Catabolic manipulation ties into the concept of 
metabolic flexibility mentioned previously and theoretically would not only be beneficial  for 
astrocyte bioenergetic function, but also for the ability of astrocytes to support neuronal function 
in times of stress [18, 19]. With this in mind oleoylethanolamide (OEA), a bioactive lipid mediator 
produced by glial cells after tissue damage has been shown to upregulate PPAR-α in TGF-β1 
treated astrocyte C6 cells [199]. These data indicate that OEA may attenuate astrocytic scar 
formation and improve motor function after ischemic stroke. Fatty acid supplementation may 
also be beneficial in reducing astrocyte activation and inflammation in PD. 6-hydroxydopamine 
treated male rats supplemented with omega-3 polyunsaturated fatty acids showed reduced 
GFAP and iNOS staining in the striatum and substantia nigra pars compacta indicating a 
reduction in the inflammatory profile in these animals [200]. Enhancing FAO in astrocytes using 
a synthetic peroxisome proliferator activated receptor delta agonist GW0742 may also have 
therapeutic potential in AD [201]. iPSC astrocytes generated from AD patients with a FAO 
defect showed an increase in carnitine palmitoyltransferase-I-a expression and FAO capacity 
when treated with GW0742. Similar effects in FAO were observed using GW0742 in the amyloid 
precursor protein/ presenilin 1 AD mouse model as well as reversed memory deficits, increased 
neurogenesis and reduced cortical inflammatory genes. However, in iPSCs, GW0742 did not 
protect against pro-inflammatory activation and in the mouse model, astrogliosis was 
unaffected, indicating that increasing FAO does not reverse the metabolic deficit fully. This may 
be because astrocyte metabolic adaptation to fatty acid dependent respiration in times of 
glucose hypometabolism (as observed in AD for example [21] comes at a cost. Recent work in 
primary astrocytes has suggested that glucose starvation leads to activation of 5' adenosine 
monophosphate-activated protein kinase. This causes a concomitant upregulation of uncoupled, 
fatty acid dependent mitochondrial respiration with reduced coupling efficiency [127], potentially 
leading to enhanced oxidative stress. With these data in mind and in combination with the 
earlier discussion around the links between certain fatty acids and inflammation, careful 
mechanistic analysis must be performed to fully elucidate the action of any potential lipid based 
metabolic interventions including high fat diets. 
5. Conclusions 
Astrocytes play a key role in the CNS from maintenance of the BBB, cell to cell communication 
and maintenance of metabolic homeostasis. Astrocyte lipids play a crucial role in these 
functions from maintaining membrane flexibility, reducing inflammation and influencing organelle 
structure and intracellular signalling. The differential use of lipids in astrocytes compared to, for 
example neurons, plays a key protective role in the CNS. This review article has summarised 
the current, ongoing research in the area of astrocyte lipid metabolism and contextualized those 
findings with historical scientific research in the CNS. We have highlighted throughout, key 
emerging areas in lipid function in astrocytes and the importance of these pathways in both 
health and disease and also astrocyte metabolic function as a whole. The emerging field of 
astrocyte LD storage has revealed the links between astrocyte lipid metabolism, oxidative 
stress, metabolic function, lipid signaling and anti-inflammatory pathways. Disruption in these 
pathways can alter the metabolic balance in the CNS causing energy generation dysregulation, 
inflammation, excitotoxicity and toxicity, which are pathogenic mechanisms relevant to many 
neurodegenerative disorders including ALS, PD, AD and ischemic stroke to name a few. Further 
characterisation of the pathways in health and disease will aid the understanding of the 
mechanisms behind these pathogenic mechanisms and will identify novel therapeutic targets or 
nutritional supplementation strategies to help ameliorate the dysfunction and benefit patients.     
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Figure Legends 
Figure 1. Intracellular lipid localisation in astrocytes and astrocyte-neuron 
communication. 
Demonstrated is the intracellular localisation of sterol lipids (SL), phospholipids (PL), 
triacylglycerol’s (TAG), fatty acids (FAs) and sphingolipids (SpL). (A) FAs are the precursor for 
most types of lipids (excluding sterol lipids) and are synthesised and stored in the cytosol (as 
shown). Sterol lipids, phospholipids and sphingolipids are important in maintaining astrocyte cell 
and organelle membranes including mitochondria and can be metabolised to produce regulatory 
molecules for intracellular processes. Triacylglycerol’s are mainly synthesised and located in the 
endoplasmic reticulum (ER). Astrocytes metabolically communicate with neurons via 
monocarboxylate transporters (MCT1/2) including supplying neurons with lactate according to 
the lactate shuttle hypothesis. As shown, (B) an influx of glutamate into astrocytes, co-
transported with Na+ from the neuronal synapse, results in glucose uptake into astrocytes via 
Glut-1 receptors (C). (D) Glucose is metabolised to pyruvate which either enters the 
mitochondria or (E) is dehydrogenated to lactate by LDH. (F) Lactate is then transported out of 
astrocytes via MCT1 receptors, and taken up by MCT2 receptors on neurons. (G) Lactate is 
then converted back to pyruvate via neuronal LDH (or glucose is taken up by Glut-3 on neurons 
and oxidised to pyruvate) where it can then enter the mitochondria and be converted to acetyl 
CoA.  
Figure 2. Phosphatidylethanolamine promotes neural stem cell differentiation into 
astrocytes, whilst phosphatidylcholine inhibits differentiation to astrocytes.  
Phosphatidylethanolamine (PtE) binds to phosphatidylethanolamine binding protein (PEBP), 
inhibiting its inhibitory action of mitogen-activated protein kinase (MAPK), which promotes 
differentiation into astrocytes. Phosphatidylcholine (PtC) exposure activates protein kinase A 
(PKA), which promotes differentiation into neurons and inhibits differentiation to astrocytes.  
Figure 3. Schematic representation of the influence of different structural lipids on 
astrocyte function.  
Saturated fatty acid exposure promotes astrogliosis by activation of mitogen-activated protein 
kinase (MAPK). During astrogliosis, PUFA production increases, leading to an increase in 
docosahexaenoic acid (DHA) extracellularly, which can inhibit astrogliosis. Sterol regulatory 
element binding protein 2 (SREBP2) promotes synthesis of cholesterol, that regulates lipid raft 
formation and inhibits glucose transporter 1 (GLUT1) translocation to the membrane. Astrocyte 
production of cholesterol and gangliosides promotes neuron outgrowth in nearby neurons. 
Changes to ceramide concentrations in astrocyte membranes observed in various neurological 
diseases implicate them in cellular functions such as inflammation and apoptosis.        
Figure 4. Lipid droplet synthesis in astrocytes 
 
Lipid droplet synthesis occurs in the ER in a triphasic process (A): (i) Nucleation-neutral lipids 
accumulate in the ER bilayer (ii) Growth–LDs form into a sphere and are wrapped in the ER 
bilayer as neutral lipids accumulate (iii) Budding–LDs then bud off into the cytosol. Fuel for this 
synthesis comes in the form of FAs which are converted into neutral lipids in the ER. In 
astrocytes FAs for neutral lipid synthesis can come from the following sources: (B) Excess 
neuronal FAs - FAs complex with Apo-lipoproteins which are then shuttled to astrocytes and 
broken down by lysosomes; FAs derived from this process subsequently enter the ER. (C) 
Dietary FAs- FAs from the diet cross the BBB by binding with FABPs that transport them 
through transporters such as CD36. LDs generated in the ER can then be metabolised by β-
oxidation to provide metabolic support for neurons (D).  
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